[1]
|
McMahon, B.J. (2009) The Natural History of Chronic Hepatitis B Virus Infection. Hepatology, 49, S45-S55. https://doi.org/10.1002/hep.22898
|
[2]
|
Van Vlerken, L.G., Arends, P., Lieveld, F.I., et al. (2015) Real Life Adherence of Chronic Hepatitis B Patients to Entecavir Treatment. Digestive and Liver Disease, 47, 577-583. https://doi.org/10.1016/j.dld.2015.03.024
|
[3]
|
Ott, J.J., Stevens, G.A., Groeger, J., et al. (2012) Global Epidemiology of Hepatitis B Virus Infection: New Estimates of Age-Specific HBsAg Seroprevalence and Endemicity. Vaccine, 30, 2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116
|
[4]
|
Torre, L.A., Bray, F., Siegel, R.L., et al. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108. https://doi.org/10.3322/caac.21262
|
[5]
|
Song, P., Gao, J., Inagaki, Y., et al. (2013) Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatoc Ellular Carcinoma in Japan and China. Liver Cancer, 2, 31-39. https://doi.org/10.1159/000346220
|
[6]
|
Chinese Society of Hepatology and Chinese Society of Infectious Diseas (2011) The Guideline of Prevention and Treatment for Chronic Hepatitis B (2010 Version). Chinese Journal of Epidemiology, 32, 405-415.
|
[7]
|
Terrault, N.A., Bzowej, N.H., Chang, K.-M., et al. (2016) AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology, 63, 261-283. https://doi.org/10.1002/hep.28156
|
[8]
|
Park, J.W., Kwak, K.M., Kim, S.E., et al. (2017) Comparison of the Long-Term Efficacy between Entecavir and Tenofovir in Treatment-Naïve Chronic Hepatitis B Patients. BMC Gastroenterology, 17, Article No. 39. https://doi.org/10.1186/s12876-017-0596-7
|
[9]
|
Lok, A.S.F. and Mcmahon, B.J. (2009) Chronic Hepatitis B: Update 2009. Hepatology, 50, 661-662. https://doi.org/10.1002/hep.23190
|
[10]
|
Manolakopoulos, S., Karatapanis, S., Elefsiniotis, J., et al. (2004) Clinical Course of Lamivudine Monotherapy in Patients with Decompensated Cirrhosis Due to HBeAg Negative Chronic HBV Infection. American Journal of Gastroenterology, 99, 57-63. https://doi.org/10.1046/j.1572-0241.2003.04021.x
|
[11]
|
Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., et al. (2018) Factors Associated with Non-Adherence to HBV Antiviral Therapy. Antiviral Therapy, 23, 425-433. https://doi.org/10.3851/IMP3219
|
[12]
|
Papatheodoridis, G., Vlachogiannakos, I., Cholongitas, E., et al. (2016) Discontinuation of Oral Antivirals in Chronic Hepatitis B: A Systematic Review. Hepatology, 63, 1481-1492. https://doi.org/10.1002/hep.28438
|
[13]
|
Shin, J.W., Jung, S.W., Lee, S.B., et al. (2018) Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated with Entecavir. American Journal of Gastroenterology, 113, 998-1008. https://doi.org/10.1038/s41395-018-0093-9
|
[14]
|
Hongthanakorn, C., Chotiyaputta, W., Oberhelman, K., et al. (2011) Virological Breakthrough and Resistance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogues in Clinical Practice. Hepatology, 53, 1854-1863. https://doi.org/10.1002/hep.24318
|
[15]
|
Ha, N.B., Ha, N.B., Garcia, R.T., et al. (2011) Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e Antigen-Negative Chronic Hepatitis B. Digestive Diseases and Sciences, 56, 2423-2431. https://doi.org/10.1007/s10620-011-1610-5
|
[16]
|
Kamezaki, H., Kanda, T., Wu, S., et al. (2011) Emergence of Entecavir-Resistant Mutations in Nucleos(t)ide-Naive Japanese Patients Infected with Hepatitis B Virus: Virological Breakthrough Is Also Dependent on Adherence to Medication. Scandinavian Journal of Gastroenterology, 46, 1111-1117. https://doi.org/10.3109/00365521.2011.584898
|
[17]
|
Shin, J.W., Jeong, J., Jung, S.W., et al. (2021) Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Digestive Diseases and Sciences, 66, 1739-1750. https://doi.org/10.1007/s10620-020-06375-3
|
[18]
|
Nayagam, S., Thursz, M., Sicuri, E., et al. (2016) Requirements for Global Elimination of Hepatitis B: A Modelling Study. The Lancet Infectious Diseases, 16, 1399-1408. https://doi.org/10.1016/S1473-3099(16)30204-3
|
[19]
|
Lee, M. and Keeffe, E.B. (2011) Study of Adherence Comes to the Treatment of Chronic Hepatitis B. Journal of Hepatology, 54, 6-8. https://doi.org/10.1016/j.jhep.2010.09.003
|
[20]
|
Vrijens, B., De Geest, S., Hughes, D.A., et al. (2012) A New Taxonomy for Describing and Defining Adherence to Medications. British Journal of Clinical Pharmacology, 73, 691-705. https://doi.org/10.1111/j.1365-2125.2012.04167.x
|
[21]
|
Osterberg, L. and Blaschke, T. (2005) Adherence to Medication. The New England Journal of Medicine, 353, 487-497. https://doi.org/10.1056/NEJMra050100
|
[22]
|
Bramley, T.J., Gerbino, P.P., Nightengale, B.S., et al. (2006) Relationship of Blood Pressure Control to Adherence with Antihypertensive Monotherapy in 13 Managed Care Organizations. Journal of Managed Care Pharmacy, 12, 239-245. https://doi.org/10.18553/jmcp.2006.12.3.239
|
[23]
|
Bouchard, M.-H., Dragomir, A., Blais, L., et al. (2007) Impact of Adherence to Statins on Coronary Artery Disease in Primary Prevention. British Journal of Clinical Pharmacology, 63, 698-708. https://doi.org/10.1111/j.1365-2125.2006.02828.x
|
[24]
|
Paterson, D.L., Swindells, S., Mohr, J., et al. (2000) Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. Annals of Internal Medicine, 133, 21-30. https://doi.org/10.7326/0003-4819-133-1-200007040-00004
|
[25]
|
Greenlaw, S.M., Yentzer, B.A., O’Neill, J.L., et al. (2010) Assessing Adherence to Dermatology Treatments: A Review of Self-Report and Electronic Measures. Skin Research and Technology, 16, 253-258. https://doi.org/10.1111/j.1600-0846.2010.00431.x
|
[26]
|
Liu, H., Golin, C.E., Miller, L.G., et al. (2001) A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors. Annals of Internal Medicine, 134, 968-977. https://doi.org/10.7326/0003-4819-134-10-200105150-00011
|
[27]
|
Chotiyaputta, W., Hongthanakorn, C., Oberhelman, K., et al. (2012) Adherence to Nucleos(t)ide Analogues for Chronic Hepatitis B in Clinical Practice and Correlation with Virological Breakthroughs. Journal of Viral Hepatitis, 19, 205-212. https://doi.org/10.1111/j.1365-2893.2011.01494.x
|
[28]
|
Chesney, M.A. (2000) Factors Affecting Adherence to Antiretroviral Therapy. Clinical Infectious Diseases, 30, S171-S176. https://doi.org/10.1086/313849
|
[29]
|
Weidenbacher, H.J., Beadles, C.A., Maciejewski, M.L., et al. (2015) Extent and Reasons for Nonadherence to Antihypertensive, Cholesterol, and Diabetes Medications: The Association with Depressive Symptom Burden in a Sample of American Veterans. Patient Preference and Adherence, 9, 327-336. https://doi.org/10.2147/PPA.S74531
|
[30]
|
Granger, B.B. (2015) Self-Reported Medication Adherence for Heart Failure Is Associated with Lower Risk of All-Cause Hospitalisation and Death. Evidence-Based Nursing, 18, 123. https://doi.org/10.1136/eb-2014-102011
|
[31]
|
Haynes, R.B., Mcdonald, H.P. and Garg, A.X. (2002) Helping Patients Follow Prescribed Treatment: Clinical Applications. JAMA, 288, 2880-2883. https://doi.org/10.1001/jama.288.22.2880
|
[32]
|
Burkhart, P.V. and Sabaté, E. (2003) Adherence to Long-Term Therapies: Evidence for Action. Journal of Nursing Scholarship, 35, 207. https://doi.org/10.1111/j.1547-5069.2003.tb00001.x
|
[33]
|
Lieveld, F.I., Van Vlerken, L.G., Siersema, P.D., et al. (2013) Patient Adherence to Antiviral Treatment for Chronic Hepatitis B and C: A Systematic Review. Annals of Hepatology, 12, 380-391. https://doi.org/10.1016/S1665-2681(19)31000-2
|
[34]
|
Kamezaki, H., Kanda, T., Arai, M., et al. (2013) Adherence to Medication Is a More Important Contributor to Viral Breakthrough in Chronic Hepatitis B Patients Treated with Entecavir than in Those with Lamivudine. International Journal of Medical Sciences, 10, 567-574. https://doi.org/10.7150/ijms.5795
|
[35]
|
Allard, N., Dev, A., Dwyer, J., et al. (2017) Factors Associated with Poor Adherence to Antiviral Treatment for Hepatitis B. Journal of Viral Hepatitis, 24, 53-58. https://doi.org/10.1111/jvh.12582
|
[36]
|
Chotiyaputta, W., Peterson, C., Ditah, F.A., et al. (2011) Persistence and Adherence to Nucleos(t)ide Analogue Treatment for Chronic Hepatitis B. Journal of Hepatology, 54, 12-18. https://doi.org/10.1016/j.jhep.2010.06.016
|
[37]
|
Sethi, A.K., Celentano, D.D., Gange, S.J., et al. (2003) Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance. Clinical Infectious Diseases, 37, 1112-1118. https://doi.org/10.1086/378301
|
[38]
|
Manolakopoulos, S., Striki, A., Papastergiou, V., et al. (2020) Persistence and Adherence to Nucleos(t)ide Analogues in Chronic Hepatitis B: A Multicenter Cohort Study. European Journal of Gastroenterology & Hepatology, 32, 635-641. https://doi.org/10.1097/MEG.0000000000001558
|
[39]
|
罗发燕, 陈铁霞, 罗平平, 等. 慢性乙型肝炎患者服药依从性调查[J]. 预防医学, 2023, 35(11): 966-969, 974.
|
[40]
|
Morisky, D.E., Ang, A., Krousel-Wood, M., et al. (2008) Predictive Validity of a Medication Adherence Measure in an Outpatient Setting. The Journal of Clinical Hypertension, 10, 348-354. https://doi.org/10.1111/j.1751-7176.2008.07572.x
|
[41]
|
韩宗儒, 闵晓春, 沈启刚, 等. 慢性乙型肝炎患者服用核苷(酸)类药物的依从性调查及其影响因素分析[J]. 肝脏, 2020, 25(11): 1148-1152.
|
[42]
|
Xu, K., Liu, L.-M., Farazi, P.A., et al. (2018) Adherence and Perceived Barriers to Oral Antiviral Therapy for Chronic Hepatitis B. Global Health Action, 11, Article 1433987. https://doi.org/10.1080/16549716.2018.1433987
|
[43]
|
Giang, L., Selinger, C.P. and Lee, A.U. (2012) Evaluation of Adherence to Oral Antiviral Hepatitis B Treatment Using Structured Questionnaires. World Journal of Hepatology, 4, 43-49.
|
[44]
|
Sogni, P., Carrieri, M.P., Fontaine, H., et al. (2012) The Role of Adherence in Virological Suppression in Patients Receiving Anti-HBV Analogues. Antiviral Therapy, 17, 395-400. https://doi.org/10.3851/IMP1944
|
[45]
|
Berg, T., Marcellin, P., Zoulim, F., et al. (2010) Tenofovir Is Effective Alone or with Emtricitabine in Adefovir-Treated Patients with Chronic-Hepatitis B Virus Infection. Gastroenterology, 139, 1207-1217. https://doi.org/10.1053/j.gastro.2010.06.053
|
[46]
|
Qiu, Q., Duan, X.-W., Li, Y., et al. (2015) Impact of Partial Reimbursement on Hepatitis B Antiviral Utilization and Adherence. World Journal of Gastroenterology, 21, 9588-9597. https://doi.org/10.3748/wjg.v21.i32.9588
|
[47]
|
Zhang, Z.P., Premikha, M., Luo, M., et al. (2021) Diabetes Distress and Peripheral Neuropathy Are Associated with Medication Non-Adherence in Individuals with Type 2 Diabetes in Primary Care. Acta Diabetologica, 58, 309-317. https://doi.org/10.1007/s00592-020-01609-2
|
[48]
|
Abegaz, T.M., Shehab, A., Gebreyohannes, E.A., et al. (2017) Nonadherence to Antihypertensive Drugs: A Systematic Review and Meta-Analysis. Medicine, 96, e5641. https://doi.org/10.1097/MD.0000000000005641
|
[49]
|
Stone, V.E., Hogan, J.W., Schuman, P., et al. (2001) Antiretroviral Regimen Complexity, Self-Reported Adherence, and HIV Patients’ Understanding of Their Regimens: Survey of Women in the HER Study. Journal of Acquired Immune Deficiency Syndromes, 28, 124-131. https://doi.org/10.1097/00126334-200110010-00003
|
[50]
|
Gellad, W.F., Grenard, J.L. and Marcum, Z.A. (2011) A Systematic Review of Barriers to Medication Adherence in the Elderly: Looking Beyond Cost and Regimen Complexity. The American Journal of Geriatric Pharmacotherapy, 9, 11-23. https://doi.org/10.1016/j.amjopharm.2011.02.004
|
[51]
|
Benner, J.S., Chapman, R.H., Petrilla, A.A., et al. (2009) Association between Prescription Burden and Medication Adherence in Patients Initiating Antihypertensive and Lipid-Lowering Therapy. American Journal of Health-System Pharmacy, 66, 1471-1477. https://doi.org/10.2146/ajhp080238
|
[52]
|
Lee, J., Cho, S., Kim, H.J., et al. (2021) High Level of Medication Adherence Is Required to Lower Mortality in Patients with Chronic Hepatitis B Taking Entecavir: A Nationwide Cohort Study. Journal of Viral Hepatitis, 28, 353-363. https://doi.org/10.1111/jvh.13418
|
[53]
|
Hilleret, M.N., Larrat, S., Stanke-Labesque, F., et al. (2011) Does Adherence to Hepatitis B Antiviral Treatment Correlate with Virological Response and Risk of Breakthrough? Journal of Hepatology, 55, 1468-1469. https://doi.org/10.1016/j.jhep.2011.04.006
|
[54]
|
Chi, H., Japhary, A., De Man, R.A., et al. (2018) Younger Age and Language Barriers Are Associated with Nonadherence to Clinical Follow-Up in Hepatitis B Treatment. Journal of Viral Hepatitis, 25, 1216-1219. https://doi.org/10.1111/jvh.12920
|
[55]
|
Li, Y., Chen, A., Wang, H., et al. (2021) Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study. Patient Preference and Adherence, 15, 1729-1738. https://doi.org/10.2147/PPA.S317250
|
[56]
|
Tütüncü, E.E., Güner, R., Gürbüz, Y., et al. (2017) Adherence to Nucleoside/Nucleotide Analogue Treatment in Patients with Chronic Hepatitis B. Balkan Medical Journal, 34, 540-545. https://doi.org/10.4274/balkanmedj.2016.1461
|
[57]
|
Hill, A., Gotham, D., Cooke, G., et al. (2015) Analysis of Minimum Target Prices for Production of Entecavir to Treat Hepatitis B in High-and Low-Income Countries. Journal of Virus Eradication, 1, 103-110. https://doi.org/10.1016/S2055-6640(20)30484-2
|
[58]
|
European Association for the Study of the Liver and European Association for the Study of the Liver (2017) EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398.
|
[59]
|
Peng, J., Yin, J., Cai, S., et al. (2015) Factors Associated with Adherence to Nucleos(t)ide Analogs in Chronic Hepatitis B Patients: Results from a 1-Year Follow-Up Study. Patient Preference and Adherence, 9, 41-45. https://doi.org/10.2147/PPA.S71510
|
[60]
|
Kayaaslan, B. and Guner, R. (2017) Adverse Effects of Oral Antiviral Therapy in Chronic Hepatitis B. World Journal of Hepatology, 9, 227-241. https://doi.org/10.4254/wjh.v9.i5.227
|